Industry News
Biotechnology Industry News
Both Seaport and Hemab are hoping…
Both Seaport and Hemab are hoping to bring in around $180 million each from their public listings this week, in the latest sign that biotech IPOs are regaining their momentum.
Compass Therapeutics shed half its…
Compass Therapeutics shed half its stock price this morning as investors digested its bispecific antibody’s failure to hit an overall survival (OS) endpoint in a phase 2/3 study.
Astellas Pharma has done some…
Astellas Pharma has done some spring cleaning of its pipeline, dropping two phase 1 candidates and slamming the brakes on a troubled gene therapy.
Oruka Therapeutics’ long-acting…
Oruka Therapeutics’ long-acting plaque psoriasis candidate cleared the skin of 63.5% of patients in a phase 2a trial, leading Jefferies analysts to predict the asset could beat out AbbVie’s Skyrizi and generate sales of up
A phase 3 trial of Intellia…
A phase 3 trial of Intellia Therapeutics’ in vivo gene editing therapy lonvoguran ziclumeran has hit its primary endpoint, leading the biotech to start a rolling submission for FDA approval.
Eli Lilly’s run of near-weekly…
Eli Lilly’s run of near-weekly acquisitions still shows no sign of letting up, with the Big Pharma now buying Ajax Therapeutics for its clinical-stage myelofibrosis therapy.
The 552 million pounds ($747…
The 552 million pounds ($747 million) raised by British biotechs in the first quarter of the year has been hailed as a “sign of recovery,” although an anticipated resurgence of IPOs across the nation has
The FDA is awarding national…
The FDA is awarding national priority vouchers to Compass Pathways, Usona Institute and Transcend Therapeutics for their psychedelic treatments. A third recipient in this batch is Transcend Therapeutics, which is being acquired by Otsuka, according
Avalyn Pharma is hoping to rake in…
Avalyn Pharma is hoping to rake in around $181.8 million from an IPO, which the biotech will use to take its inhaled versions of approved drugs for respiratory conditions into late-stage studies.
Two months after bringing in…
Two months after bringing in Michael Cola to man the helm at Helus Pharma, the company’s board has requested his departure, effective immediately. As such, co-founder and executive chairman Eric So will again take on
Despite the recent “feeding…
Despite the recent “feeding frenzy,” Pitchbook’s Ben Zercher told Fierce he expects in vivo CAR-T dealmaking to slow due to a shortage of viable acquisition targets.
Pfizer has abandoned work on a…
Pfizer has abandoned work on a PD-L1-targeting drug that was being tested in patients with various cancers.
While Big Pharmas embarked on a…
While Big Pharmas embarked on a frenzy of acquisitions over recent weeks, Roche’s CEO has explained to Fierce why the Swiss drugmaker is happy to sit this round out.
As Sanofi counts down the days…
As Sanofi counts down the days before its new leader arrives, the pharma's CFO acknowledged to Fierce that there have been a “certain number of setbacks.”
Just a few months after ripping up…
Just a few months after ripping up the central nervous system-focused portion of its RIPK1 deal with Rigel Pharmaceuticals, Eli Lilly has now thrown out the rest of the pact, too.
Kurma Partners has closed its…
Kurma Partners has closed its fourth biotech venture capital fund after raising 215 million euros ($252 million) to support European startups.
A little over a year after…
A little over a year after reabsorbing its anticoagulant abelacimab, Novartis has now terminated two phase 3 trials for the antibody.
Kyverna Therapeutics has unveiled…
Kyverna Therapeutics has unveiled the full results from its registrational trial of miv-cel in stiff person syndrome (SPS), providing a comprehensive look at what could become the first-ever CAR-T therapy approved for an autoimmune disease.
Roche has shared details of…
Roche has shared details of fatalities in its phase 3 relapsing multiple sclerosis trials, revealing that deaths from infections, diabetes complications and an accident contributed to an imbalance between the fenebrutinib and control cohorts.
A pair of Sage veterans has…
A pair of Sage veterans has launched a neurology-focused startup armed with $106 million and a clinical-stage pipeline of assets licensed from Eisai and Hansoh.